We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BAER:SIXJulius Baer Gruppe AG Analysis

Data as of 2026-03-11 - not real-time

$2.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Bridger Aerospace is trading at $2, right on its identified support level, while both the 20‑day and 50‑day SMAs sit above the market price ($2.48 and $2.53 respectively), indicating a short‑term downtrend. The RSI of 31.5 suggests the stock is oversold, yet the MACD remains bearish and the trend is classified as neutral, underscoring mixed technical signals. Volatility is exceptionally high at over 75% and beta exceeds 1.1, pointing to a price that can swing sharply on news. Market sentiment is extreme greed (76.9 on the Fear & Greed Index) and analysts have issued a single "strong buy" rating with a median target of $5, implying a potential 150% upside.
Fundamentally, the company faces severe pressure: revenue has contracted by 45%, operating margin is a disastrous -190%, and free cash flow is a negative $52.9 M. Debt is overwhelming, with a debt‑to‑equity ratio of 379 and a book value per share of -$6.13, making the balance sheet highly leveraged. Recent earnings missed expectations, triggering a 13% share‑price decline, while a new COO has been appointed to bolster execution. The combination of distressed financials, high leverage, and volatile price action makes the stock a high‑risk play despite the attractive upside narrative.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price at support with bearish MACD
  • High leverage and negative cash flow
  • Recent earnings miss and 13% price drop

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Potential upside to $5 target
  • Oversold technical position (RSI)
  • Management change (new COO) may improve execution

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Strategic niche in aerial firefighting with limited competition
  • Extreme greed sentiment indicating market optimism
  • Possible restructuring of debt and balance‑sheet improvement

Key Metrics & Analysis

Financial Health

Revenue Growth-45.20%
Profit Margin3.37%
ROE7.01%
ROA3.07%
Debt/Equity378.79
P/B Ratio-0.3
Op. Cash Flow$16.7M
Free Cash Flow$-52949624
Industry P/E29.4

Technical Analysis

TrendNeutral
RSI31.5
Support$2.00
Resistance$3.03
MA 20$2.48
MA 50$2.53
MA 200$1.98
MACDBearish
VolumeStable
Fear & Greed Index76.91

Valuation

Target Price$5.00
Upside/Downside150.00%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.17
Volatility75.46%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.